vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $339.5M, roughly 1.8× Westrock Coffee Co). Royalty Pharma plc runs the higher net margin — 34.4% vs -6.6%, a 41.1% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 4.8%). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
RPRX vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $339.5M |
| Net Profit | $214.2M | $-22.6M |
| Gross Margin | — | 11.5% |
| Operating Margin | 62.4% | -2.6% |
| Net Margin | 34.4% | -6.6% |
| Revenue YoY | 4.8% | 48.3% |
| Net Profit YoY | 2.9% | 8.3% |
| EPS (diluted) | $0.49 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $339.5M | ||
| Q3 25 | $609.3M | $354.8M | ||
| Q2 25 | $578.7M | $280.9M | ||
| Q1 25 | $568.2M | $213.8M | ||
| Q4 24 | $593.6M | $229.0M | ||
| Q3 24 | $564.7M | $220.9M | ||
| Q2 24 | $537.3M | $208.4M | ||
| Q1 24 | $568.0M | $192.5M |
| Q4 25 | $214.2M | $-22.6M | ||
| Q3 25 | $288.2M | $-19.1M | ||
| Q2 25 | $30.2M | $-21.6M | ||
| Q1 25 | $238.3M | $-27.2M | ||
| Q4 24 | $208.2M | $-24.6M | ||
| Q3 24 | $544.0M | $-14.3M | ||
| Q2 24 | $102.0M | $-17.8M | ||
| Q1 24 | $4.8M | $-23.7M |
| Q4 25 | — | 11.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 14.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 19.4% |
| Q4 25 | 62.4% | -2.6% | ||
| Q3 25 | 70.1% | -2.4% | ||
| Q2 25 | 36.3% | -5.3% | ||
| Q1 25 | 94.0% | -6.1% | ||
| Q4 24 | 60.9% | -4.3% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | 50.2% | -7.9% | ||
| Q1 24 | -13.0% | -5.3% |
| Q4 25 | 34.4% | -6.6% | ||
| Q3 25 | 47.3% | -5.4% | ||
| Q2 25 | 5.2% | -7.7% | ||
| Q1 25 | 41.9% | -12.7% | ||
| Q4 24 | 35.1% | -10.7% | ||
| Q3 24 | 96.3% | -6.5% | ||
| Q2 24 | 19.0% | -8.5% | ||
| Q1 24 | 0.8% | -12.3% |
| Q4 25 | $0.49 | $-0.22 | ||
| Q3 25 | $0.67 | $-0.20 | ||
| Q2 25 | $0.07 | $-0.23 | ||
| Q1 25 | $0.55 | $-0.29 | ||
| Q4 24 | $0.46 | $-0.26 | ||
| Q3 24 | $1.21 | $-0.16 | ||
| Q2 24 | $0.23 | $-0.20 | ||
| Q1 24 | $0.01 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $49.9M |
| Total DebtLower is stronger | $9.0B | $444.1M |
| Stockholders' EquityBook value | $9.7B | $-1.9M |
| Total Assets | $19.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $49.9M | ||
| Q3 25 | $938.9M | $34.0M | ||
| Q2 25 | $631.9M | $44.0M | ||
| Q1 25 | $1.1B | $33.1M | ||
| Q4 24 | $929.0M | $26.2M | ||
| Q3 24 | $950.1M | $22.4M | ||
| Q2 24 | $1.8B | $24.3M | ||
| Q1 24 | $843.0M | $12.6M |
| Q4 25 | $9.0B | $444.1M | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | $393.1M | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $-1.9M | ||
| Q3 25 | $9.6B | $11.4M | ||
| Q2 25 | $9.5B | $18.2M | ||
| Q1 25 | $9.8B | $71.4M | ||
| Q4 24 | $10.3B | $97.5M | ||
| Q3 24 | $10.3B | $110.3M | ||
| Q2 24 | $9.8B | $81.5M | ||
| Q1 24 | $9.9B | $91.7M |
| Q4 25 | $19.6B | $1.2B | ||
| Q3 25 | $19.3B | $1.2B | ||
| Q2 25 | $18.3B | $1.2B | ||
| Q1 25 | $17.6B | $1.1B | ||
| Q4 24 | $18.2B | $1.1B | ||
| Q3 24 | $18.0B | $1.1B | ||
| Q2 24 | $17.7B | $1.1B | ||
| Q1 24 | $16.1B | $983.3M |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | 4.03× | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $36.7M |
| Free Cash FlowOCF − Capex | — | $27.8M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $36.7M | ||
| Q3 25 | $702.6M | $-26.6M | ||
| Q2 25 | $364.0M | $-7.0M | ||
| Q1 25 | $596.1M | $-22.1M | ||
| Q4 24 | $742.5M | $2.8M | ||
| Q3 24 | $703.6M | $-332.0K | ||
| Q2 24 | $658.2M | $-23.7M | ||
| Q1 24 | $664.6M | $8.0M |
| Q4 25 | — | $27.8M | ||
| Q3 25 | — | $-44.7M | ||
| Q2 25 | — | $-27.5M | ||
| Q1 25 | — | $-63.4M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | — | $-36.7M | ||
| Q2 24 | — | $-59.9M | ||
| Q1 24 | — | $-60.9M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -12.6% | ||
| Q2 25 | — | -9.8% | ||
| Q1 25 | — | -29.7% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | — | -16.6% | ||
| Q2 24 | — | -28.7% | ||
| Q1 24 | — | -31.7% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 19.3% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 35.8% |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | — | ||
| Q2 25 | 12.06× | — | ||
| Q1 25 | 2.50× | — | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 6.45× | — | ||
| Q1 24 | 139.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
